298 related articles for article (PubMed ID: 16382292)
1. Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story?
Reyes AJ; Leary WP
Cardiovasc Drugs Ther; 2005 Oct; 19(5):311-3. PubMed ID: 16382292
[TBL] [Abstract][Full Text] [Related]
2. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
Hare JM; Mangal B; Brown J; Fisher C; Freudenberger R; Colucci WS; Mann DL; Liu P; Givertz MM; Schwarz RP;
J Am Coll Cardiol; 2008 Jun; 51(24):2301-9. PubMed ID: 18549913
[TBL] [Abstract][Full Text] [Related]
3. Oxipurinol: alloxanthine, Oxyprim, oxypurinol.
Drugs R D; 2004; 5(3):171-5. PubMed ID: 15139781
[TBL] [Abstract][Full Text] [Related]
4. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: molecular mechanisms and clinical implications.
Puddu P; Puddu GM; Cravero E; Vizioli L; Muscari A
J Cardiol; 2012 May; 59(3):235-42. PubMed ID: 22398104
[TBL] [Abstract][Full Text] [Related]
5. The ongoing search for a stratified medicine approach in heart failure.
Tang WH
J Am Coll Cardiol; 2008 Jun; 51(24):2310-2. PubMed ID: 18549914
[No Abstract] [Full Text] [Related]
6. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study.
Cingolani HE; Plastino JA; Escudero EM; Mangal B; Brown J; Pérez NG
J Card Fail; 2006 Sep; 12(7):491-8. PubMed ID: 16952781
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.
Chu WY; Annink KV; Nijstad AL; Maiwald CA; Schroth M; Bakkali LE; van Bel F; Benders MJNL; van Weissenbruch MM; Hagen A; Franz AR; Dorlo TPC; Allegaert K; Huitema ADR;
Clin Pharmacokinet; 2022 Feb; 61(2):321-333. PubMed ID: 34617261
[TBL] [Abstract][Full Text] [Related]
8. Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical.
Spector T
Biochem Pharmacol; 1988 Jan; 37(2):349-52. PubMed ID: 2829916
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise.
Kaya M; Moriwaki Y; Ka T; Inokuchi T; Yamamoto A; Takahashi S; Tsutsumi Z; Tsuzita J; Oku Y; Yamamoto T
Metabolism; 2006 Jan; 55(1):103-7. PubMed ID: 16324927
[TBL] [Abstract][Full Text] [Related]
10. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T;
Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098
[TBL] [Abstract][Full Text] [Related]
11. Purine metabolism and inhibition of xanthine oxidase in severely hypoxic neonates going onto extracorporeal membrane oxygenation.
Marro PJ; Baumgart S; Delivoria-Papadopoulos M; Zirin S; Corcoran L; McGaurn SP; Davis LE; Clancy RR
Pediatr Res; 1997 Apr; 41(4 Pt 1):513-20. PubMed ID: 9098853
[TBL] [Abstract][Full Text] [Related]
12. Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors.
Packer M
J Card Fail; 2020 Nov; 26(11):977-984. PubMed ID: 32890737
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome.
McGaurn SP; Davis LE; Krawczeniuk MM; Murphy JD; Jacobs ML; Norwood WI; Clancy RR
Pediatrics; 1994 Dec; 94(6 Pt 1):820-3. PubMed ID: 7970996
[TBL] [Abstract][Full Text] [Related]
14. Effect of furosemide on renal excretion of oxypurinol and purine bases.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
Metabolism; 2001 Feb; 50(2):241-5. PubMed ID: 11229436
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy.
Baldus S; Müllerleile K; Chumley P; Steven D; Rudolph V; Lund GK; Staude HJ; Stork A; Köster R; Kähler J; Weiss C; Münzel T; Meinertz T; Freeman BA; Heitzer T
Free Radic Biol Med; 2006 Oct; 41(8):1282-8. PubMed ID: 17015175
[TBL] [Abstract][Full Text] [Related]
16. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure.
Freudenberger RS; Schwarz RP; Brown J; Moore A; Mann D; Givertz MM; Colucci WS; Hare JM
Expert Opin Investig Drugs; 2004 Nov; 13(11):1509-16. PubMed ID: 15500398
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia.
Springer J; Tschirner A; Hartman K; Palus S; Wirth EK; Ruis SB; Möller N; von Haehling S; Argiles JM; Köhrle J; Adams V; Anker SD; Doehner W
Int J Cancer; 2012 Nov; 131(9):2187-96. PubMed ID: 22336965
[TBL] [Abstract][Full Text] [Related]
18. Effect of allopurinol on the formation of reactive oxygen species during intense exercise in the horse.
Mills PC; Smith NC; Harris RC; Harris P
Res Vet Sci; 1997; 62(1):11-6. PubMed ID: 9160417
[TBL] [Abstract][Full Text] [Related]
19. Effects of allopurinol on beer-induced increases in plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine).
Ka T; Moriwaki Y; Inokuchi T; Yamamoto A; Takahashi S; Tsutsumi Z; Yamamoto T
Horm Metab Res; 2006 Mar; 38(3):188-92. PubMed ID: 16673211
[TBL] [Abstract][Full Text] [Related]
20. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy.
Minhas KM; Saraiva RM; Schuleri KH; Lehrke S; Zheng M; Saliaris AP; Berry CE; Barouch LA; Vandegaer KM; Li D; Hare JM
Circ Res; 2006 Feb; 98(2):271-9. PubMed ID: 16357304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
